Open Biosystems' Open Access RNAi Program Adopted by University of Copenhagen and University of ...( http://www.openbiosystems.com ...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Open Biosystems' Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland
Date:4/7/2008
http://www.openbiosystems.com
'/>"/>
| SOURCE Open Biosystems, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
2. Open Biosystems Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina
3. Sigma-Aldrich, Oxford BioMedica and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents
4. Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System
5. Primera Biosystems Raises $21 Million in Series B Private Round
6. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
7. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
8. Study Finds Broadband Access Key to Empowerment of Minority Communities
9. Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program
10. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio
Post Your Comments:
Breaking Biology Technology:Microfluidics Chairman James N. Little, Ph.D., Announces Retirement from Board of Directors 2Microfluidics Chairman James N. Little, Ph.D., Announces Retirement from Board of Directors 3Reportlinker Adds Pharmacodynamic Assays 2Reportlinker Adds Pharmacodynamic Assays 3Reportlinker Adds Pharmacodynamic Assays 4Eidogen-Sertanty Licenses TIP to the FDA 2BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 2BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 3BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 4
Other Biology Technology:Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 2Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 3Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 4Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 5Genmab Discloses Target and Development Plans for HuMax-Inflam 2Genmab Discloses Target and Development Plans for HuMax-Inflam 3New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 2New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 3New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 4
Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic DiseasesGenmab Discloses Target and Development Plans for HuMax-InflamNew Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
Breaking Biology News(10 mins):Rodent smoke screen 2Superior offspring without genetic modification 2Plate-eating good: Université de Montréal professor designs edible tableware 2Huifeng Bio Pharmaceutical Technology Reports 26 25 Quarterly Revenue Increase 6508 1Huifeng Bio Pharmaceutical Technology Reports 26 25 Quarterly Revenue Increase 6508 2Huifeng Bio Pharmaceutical Technology Reports 26 25 Quarterly Revenue Increase 6508 3Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference 6504 1In Germany children with cancer have a high probability of survival 62041 1In Germany children with cancer have a high probability of survival 62041 2In Germany children with cancer have a high probability of survival 62041 3
Other Biology News:New system would use rotating magnetic field to detect pathogens 2New system would use rotating magnetic field to detect pathogens 3New system would use rotating magnetic field to detect pathogens 4Social standing influences elephant movement 2Social standing influences elephant movement 3SCI marks expansion into Asia with the launch of SCI INDIA 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |